What Does the Clinical Trial History of HGH Look Like?

The earliest clinical use of growth hormone traces back to the mid-20th century, when researchers began treating growth hormone deficiency in children using material extracted from human cadaveric pituitary glands — a supply-limited approach that nonetheless established the basic clinical rationale for growth hormone replacement that persists today.

The transition to recombinant DNA-derived somatropin in the 1980s, prompted by safety concerns with cadaveric extraction, opened the door to the larger, more rigorous clinical trials associated with modern pharmaceutical approval processes, leading to the indications recognized today: pediatric and adult growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome among them. Since approval, post-marketing surveillance and long-term outcome studies have continued to refine understanding of the therapy's safety profile over extended use.

This is a general historical summary drawn from published clinical literature, not a source of specific study data or statistics. REVIVE LAB UAE does not sell HGH and this page makes no therapeutic claim.